MD3280727T2 - Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora - Google Patents

Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora

Info

Publication number
MD3280727T2
MD3280727T2 MDE20180158T MDE20180158T MD3280727T2 MD 3280727 T2 MD3280727 T2 MD 3280727T2 MD E20180158 T MDE20180158 T MD E20180158T MD E20180158 T MDE20180158 T MD E20180158T MD 3280727 T2 MD3280727 T2 MD 3280727T2
Authority
MD
Moldova
Prior art keywords
type
tgf
extracellular domain
beta
arm
Prior art date
Application number
MDE20180158T
Other languages
English (en)
Inventor
Ravindra Kumar
Asya Grinberg
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MD3280727T2 publication Critical patent/MD3280727T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

În anumite aspecte, dezvăluirea redă complecşi polipeptidici heteromerici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor de serină/treonină kinază tip I al familiei TGF-beta sau un domeniu extracelular al unui receptor de serină/treonină kinază tip II al familiei TGF-beta. În unele modalităţi de realizare, dezvăluirea redă complecşi polipeptidici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor tip II selectat dintre: ActRIIA, ActRIIB, TGFBRII, BMPRII, şi MISRII. În unele modalităţi de realizare, dezvăluirea redă complecşi polipeptidici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor tip I selectat dintre : ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, şi ALK7. Opţional complexul solubil este un heterodimer. În anumite aspecte, astfel de complecşi polipeptidici solubili se pot utiliza pentru tratamentul sau prevenirea a diferite afecţiuni asociate cu TGF-beta, incluzând fără limitare boli sau tulburări asociate cu, de exemplu, cancer, muşchi, os, grăsime, celule roşii din sânge, metabolism, fibroză şi alte ţesuturi care sunt afectate de unul sau mai mulţi liganzi ai superfamiliei TGF-beta.
MDE20180158T 2015-04-06 2016-04-06 Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora MD3280727T2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143579P 2015-04-06 2015-04-06
US201562259422P 2015-11-24 2015-11-24
PCT/US2016/026275 WO2016164501A1 (en) 2015-04-06 2016-04-06 Single-arm type i and type ii receptor fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MD3280727T2 true MD3280727T2 (ro) 2021-06-30

Family

ID=57015654

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180158T MD3280727T2 (ro) 2015-04-06 2016-04-06 Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora

Country Status (21)

Country Link
US (3) US10358476B2 (ro)
EP (2) EP3865505A1 (ro)
JP (2) JP6810702B2 (ro)
KR (1) KR20170141215A (ro)
CN (3) CN113683708A (ro)
AU (2) AU2016246602B2 (ro)
CA (1) CA2981793A1 (ro)
CY (1) CY1124247T1 (ro)
DK (1) DK3280727T3 (ro)
ES (1) ES2864850T3 (ro)
HK (1) HK1252958A1 (ro)
HR (1) HRP20210411T1 (ro)
HU (1) HUE054180T2 (ro)
LT (1) LT3280727T (ro)
MA (1) MA53883A (ro)
MD (1) MD3280727T2 (ro)
PL (1) PL3280727T3 (ro)
PT (1) PT3280727T (ro)
RS (1) RS61728B1 (ro)
SI (1) SI3280727T1 (ro)
WO (1) WO2016164501A1 (ro)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EA202190016A1 (ru) 2015-04-06 2021-08-31 Акселерон Фарма Инк. Гетеромультимеры рецепторов типа i и типа ii белков суперсемейства tgf-бета
LT3280727T (lt) 2015-04-06 2021-04-12 Acceleron Pharma Inc. Vienos atšakos i tipo ir ii tipo receptorių sulieti baltymai ir jų naudojimas
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
JP7320350B2 (ja) 2015-08-04 2023-08-03 アクセルロン ファーマ インコーポレイテッド 骨髄増殖性障害を処置するための方法
EP3439686A4 (en) * 2016-04-06 2019-10-09 Acceleron Pharma Inc. BMPRII POLYPEPTIDES AND USES THEREOF
EP3522912A4 (en) 2016-10-05 2020-10-14 Acceleron Pharma Inc. HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES
WO2018067879A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
US11267865B2 (en) 2016-10-05 2022-03-08 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
CN110461349A (zh) 2016-11-10 2019-11-15 科乐斯疗法公司 激活素受体iia型变体及其使用方法
CA3051696A1 (en) * 2017-02-01 2018-08-09 Acceleron Pharma Inc. Tgf.beta. and actrii antagonists for use in increasing immune activity
PL3628049T3 (pl) * 2017-05-04 2023-09-25 Acceleron Pharma Inc. Białka fuzyjne receptora TGF-beta typu II i ich zastosowania
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
US20210107959A1 (en) * 2018-01-03 2021-04-15 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
US20220211805A1 (en) * 2018-02-09 2022-07-07 Acceleron Pharma Inc. Methods for treating heterotopic ossification
EP3762421A2 (en) 2018-03-09 2021-01-13 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
CA3099527A1 (en) * 2018-05-03 2019-11-07 Acceleron Pharma Inc. Multispecific binders of tgf.beta.-superfamily ligands and uses thereof
EP3999527A4 (en) * 2019-07-18 2024-04-17 Memorial Sloan Kettering Cancer Center METHODS AND COMPOSITIONS FOR TARGETING TGF-BETA SIGNALIZING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
EP4073101A4 (en) * 2019-12-10 2024-01-10 Acceleron Pharma Inc SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHOD FOR TREATING PULMONARY HYPERTENSION
US20230134083A1 (en) * 2020-03-13 2023-05-04 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions
CN112190694B (zh) * 2020-09-17 2023-11-10 南通大学 细胞因子活化素c在治疗神经病理性疼痛方面的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2000043781A2 (en) 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
US7820620B2 (en) 2003-09-15 2010-10-26 Research Development Foundation Cripto antagonism of activin and TGF-b signaling
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
NZ568369A (en) 2005-11-23 2011-10-28 Acceleron Pharma Inc Activin-actriia antagonists and uses for promoting bone growth
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
KR20170012582A (ko) * 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
WO2008094708A2 (en) * 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
EP2140005B1 (en) 2007-03-19 2013-12-11 National Research Council of Canada Fusion proteins comprising two tgf-beta binding domains
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2009241755B2 (en) * 2008-05-02 2015-10-01 Acceleron Pharma Inc. Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
KR20190049912A (ko) * 2008-06-26 2019-05-09 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT2340031T (lt) 2008-08-14 2019-08-12 Acceleron Pharma Inc. Gdf gaudyklės, skirtos naudoti anemijos gydymui
EP2326670A4 (en) 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
PE20150680A1 (es) * 2008-11-26 2015-05-16 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
CN102548617B (zh) 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
BR122021017187B1 (pt) * 2009-06-12 2022-07-12 Acceleron Pharma Inc Ácido nucléico e polipeptídeo recombinante, preparação farmacêutica compreendendo o dito polipeptídeo e usos terapêuticos da mesma
BR112012005893A2 (pt) 2009-09-16 2016-11-22 Genentech Inc hélice enrolada e/ou complexos de proteínas contendo conectores e usos dos mesmos
FR2951408B1 (fr) 2009-10-15 2012-01-13 Renault Sa Cadre moteur pour moteur electrique de vehicule automobile
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
JP5836961B2 (ja) * 2009-11-03 2015-12-24 アクセルロン ファーマ， インコーポレイテッド 脂肪肝疾患を処置するための方法
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
EP3299388A1 (en) 2012-03-28 2018-03-28 The Board of Regents of The University of Texas System Tgf type ii-type iii receptor fusions
AU2014308751B2 (en) * 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
WO2016090035A2 (en) 2014-12-02 2016-06-09 La Jolla Institute For Allergy And Immunology Modulators of activin and methods for modulating immune responses and t follicular helper cells
KR20170129233A (ko) 2015-03-26 2017-11-24 악셀레론 파마 인코포레이티드 폴리스타틴-관련된 융합 단백질 및 이들의 용도
LT3280727T (lt) 2015-04-06 2021-04-12 Acceleron Pharma Inc. Vienos atšakos i tipo ir ii tipo receptorių sulieti baltymai ir jų naudojimas
EA202190016A1 (ru) 2015-04-06 2021-08-31 Акселерон Фарма Инк. Гетеромультимеры рецепторов типа i и типа ii белков суперсемейства tgf-бета
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
JP6959487B2 (ja) 2015-04-22 2021-11-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質
WO2016205370A1 (en) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
JP7159148B2 (ja) 2016-07-07 2022-10-24 アクセルロン ファーマ インコーポレイテッド Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018067879A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

Also Published As

Publication number Publication date
RS61728B1 (sr) 2021-05-31
AU2021200906A1 (en) 2021-03-04
PL3280727T3 (pl) 2021-07-19
EP3280727B1 (en) 2021-02-17
HRP20210411T1 (hr) 2021-04-30
ES2864850T3 (es) 2021-10-14
CN107849114B (zh) 2021-08-20
CN107849114A (zh) 2018-03-27
JP7203807B2 (ja) 2023-01-13
EP3280727A4 (en) 2019-02-13
US10358476B2 (en) 2019-07-23
EP3280727A1 (en) 2018-02-14
MA53883A (fr) 2021-08-18
AU2016246602A1 (en) 2017-10-26
JP2021054839A (ja) 2021-04-08
HK1252958A1 (zh) 2019-06-06
PT3280727T (pt) 2021-04-23
US20160289298A1 (en) 2016-10-06
US11208460B2 (en) 2021-12-28
JP2018517664A (ja) 2018-07-05
LT3280727T (lt) 2021-04-12
CN113683709A (zh) 2021-11-23
US20220315642A1 (en) 2022-10-06
US20200055920A1 (en) 2020-02-20
AU2016246602B2 (en) 2020-11-19
JP6810702B2 (ja) 2021-01-06
KR20170141215A (ko) 2017-12-22
DK3280727T3 (da) 2021-03-15
AU2021200906B2 (en) 2023-04-06
WO2016164501A1 (en) 2016-10-13
SI3280727T1 (sl) 2021-07-30
HUE054180T2 (hu) 2021-08-30
CN113683708A (zh) 2021-11-23
EP3865505A1 (en) 2021-08-18
CY1124247T1 (el) 2022-07-22
CA2981793A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
MD3280727T2 (ro) Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora
BR112017021510A2 (pt) heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
NZ747350A (en) Methods for treating anemia
ECSP055699A (es) Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos
BR112014015105A8 (pt) inibidores da via de sinalização notch e uso do mesmo no tratamento de cânceres
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
EA201100355A1 (ru) Пирролопиримидины и их применение
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
MY182036A (en) Heteroaromatic compounds as pi3 kinase modulators
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
CL2015001483A1 (es) Compuestos derivados de hidroxiquinolina y otros heterociclos nitrogenados, antagonistas de los receptores muscarínicos y agonistas del receptor beta2 adrenérgico; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento o prevencion del asma, bronquitis cronica o epoc.
WO2014096388A3 (en) Novel benzimidazole derivatives as kinase inhibitors
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201792304A1 (ru) Комбинированная терапия для лечения рака
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
PE20110572A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO INHIBIDORES DE MET
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
EA201390813A1 (ru) Антитела и их применение
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
BR112018067938A2 (pt) combinação de um antagonista de cxcr4 e inibidor de ponto de verificação imunológica
JP2017530372A5 (ro)
NZ630908A (en) Heterocyclic compounds and methods of their use
MX370789B (es) Anticuerpo anti-vegf y composición farmacéutica que comprende los mismos para usarse para prevenir, diagnosticar o tratar enfermedades relacionadas con cáncer o angiogénesis.